Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-O rollover study of continued olaparib treatment after prior AstraZeneca oncology trials
MOH_2021-11-09_010384Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in cancer, sponsored by AstraZeneca. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
cancer
Beyond the preview
Go deeper on MOH_2021-11-09_010384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-09_010384.